Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.
2.

Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.

Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F.

Eur J Endocrinol. 2001 Jan;144(1):5-11.

3.

Recombinant humane thyrotropin (rhtSH) a new aid in the diagnosis and treatment of thyroid carcinoma with radio-iodine.

Brans B, Gemmel F, De Winter O, Fiers T, De Roose J, Vermeersch H, Rubens R, Kaufman JM, Dierckx RA.

Acta Clin Belg. 2001 Sep-Oct;56(5):316-20.

PMID:
11770226
4.
5.

Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.

Driedger AA, Kotowycz N.

J Clin Endocrinol Metab. 2004 Feb;89(2):585-90.

PMID:
14764766
6.
7.

Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD.

N Engl J Med. 1997 Sep 25;337(13):888-96.

8.

Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008302. doi: 10.1002/14651858.CD008302.pub2. Review.

PMID:
21069705
9.

Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011. Epub 2011 Mar 15.

PMID:
21411300
10.

Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.

de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM.

J Nucl Med. 2004 Sep;45(9):1549-54.

11.

Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis.

Risse JH, Grünwald F, Bender H, Schüller H, Van Roost D, Biersack HJ.

Thyroid. 1999 Dec;9(12):1253-6.

PMID:
10646667
12.

Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.

Giusti M, Zoccola R, Guazzini B, Molinari E, Valenti S, Villa G, Bertolazzi L, Minuto F.

Minerva Endocrinol. 2003 Sep;28(3):191-203.

PMID:
14605601
13.

The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.

Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, Marco S, Giovanni L.

Clin Endocrinol (Oxf). 2002 Feb;56(2):247-52.

PMID:
11874417
14.

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F.

Endocr Relat Cancer. 2005 Mar;12(1):49-64. Review.

15.

Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.

David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC.

Thyroid. 2005 Feb;15(2):158-64.

PMID:
15753676
16.

Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature.

Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM.

Endocr Pract. 2000 Nov-Dec;6(6):460-4. Review.

PMID:
11155220
17.

[Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].

Gómez Camarero P, Martínez Brocca MA, Rodríguez Rodríguez JR, Navarro González E, Tirado Hospital JL, González Duarte D, Vázquez Albertino R, Astorga Jimenez R.

Rev Esp Med Nucl. 2003 Sep-Oct;22(5):295-305. Spanish.

18.

Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.

Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V.

Eur J Endocrinol. 2003 Jan;148(1):19-24.

19.

Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.

Robbins RJ, Driedger A, Magner J; U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group.

Thyroid. 2006 Nov;16(11):1121-30.

PMID:
17123339
20.

Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma.

Löffler M, Weckesser M, Franzius C, Kies P, Schober O.

Nuklearmedizin. 2003 Dec;42(6):240-3.

PMID:
14668956

Supplemental Content

Support Center